Motus GI Holdings, Inc. (MOTS)
| Market Cap | 2.80M |
| Revenue (ttm) | 556,000 |
| Net Income (ttm) | -16.03M |
| Shares Out | 5.89M |
| EPS (ttm) | -3.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 38,009 |
| Open | 0.460 |
| Previous Close | 0.475 |
| Day's Range | 0.460 - 0.485 |
| 52-Week Range | 0.430 - 4.810 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 4.25 (+794.74%) |
| Earnings Date | Nov 13, 2023 |
About MOTS
Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. Motus GI Holdings, Inc. was founded in 2008 and is based in Fort Lauderdale, Florida. [Read more]
Financial Performance
In 2022, MOTS's revenue was $592,000, an increase of 51.41% compared to the previous year's $391,000. Losses were -$18.60 million, -26.14% less than in 2021.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for MOTS stock is "Strong Buy." The 12-month stock price forecast is $4.25, which is an increase of 794.74% from the latest price.
News
Motus GI Submits Special 510(k) to FDA for Pure-Vu EVS Gen 4 Gastro and Colon
– A special 510(k), according to FDA guidance, is usually reviewed within 30 days of receipt – – Pure-Vu Gen 4 platform opens up the Upper GI market, reduces the cost-of-goods by approximately 50% and...
Motus GI Amends Royalty Agreement
– Amended agreement eliminates approximately $1.0M in contingent royalty obligations from balance sheet – – Canceled royalty rights in exchange for common stock expected to improve Company's stockhol...
Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors
-- David Hochman and Darren Sherman resign from Motus Board of Directors to focus on their executive obligations -- -- David Hochman and Darren Sherman resign from Motus Board of Directors to focus on...
Motus GI to Present at the H.C. Wainwright 25th Annual Global Investment Conference
FORT LAUDERDALE, Fla., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Reports Second Quarter 2023 Financial Results and Provides Corporate Update
FORT LAUDERDALE, Fla., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Receives Approval from the Israeli Ministry of Health to Initiate Commercial Sales of its Pure-Vu® EVS System
FORT LAUDERDALE, Fla., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Announces Purchase Agreement for the Pure-Vu System® from Banner Desert Medical Center
FORT LAUDERDALE, Fla., July 20, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Announces Pure-Vu Gen 4 Gastro and Colon System Featured at 9th IECED Live Endoscopy Course 2023 at the Pentax Learning Center
FORT LAUDERDALE, Fla., June 14, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes an...
Motus GI Announces Appointment of Ravit Ram as Chief Financial Officer
FORT LAUDERDALE, Fla., June 05, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and...
Motus GI Announces $3.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules
FORT LAUDERDALE, Fla., May 18, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company focused on improving endoscopic outcomes and...
Motus GI Completes First Clinical Evaluation of New Pure-Vu® Gastro in Upper Gastrointestinal (GI) Procedures to Support FDA Submission
- Pure-Vu Gastro achieves high usability scores in supporting upper endoscopy procedures with first time users - - On track to submit a 510(k) to the U.S. FDA for the Pure-Vu Gen 4 Gastro device in Q4...
Motus GI Reports First Quarter 2023 Financial Results and Provides Corporate Update
■ Oral presentation at the Digestive Disease Week 2023 featured positive clinical data showing a reduction of 33% in incomplete bowel prep (IBP)in just six months after implementation of the Pure-Vu® ...
Motus GI Announces Executive Leadership Restructuring and Additional Cost Saving Initiatives to Support Near-Term Milestones
FORT LAUDERDALE, Fla. , April 13, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company focused on improving endoscopic outcomes a...
Motus GI Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
FORT LAUDERDALE, Fla., March 31, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve...
Motus GI Announces Exploration of Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring Plan
FORT LAUDERDALE, Fla., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve ...
Motus GI Reports Third Quarter 2022 Financial Results and Provides Business Update
FORT LAUDERDALE, Fla., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc. , (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve...
Motus GI to Release Third Quarter Results and Provide a Business Update on November 14
FORT LAUDERDALE, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...
Motus GI Announces Positive Clinical Data for Pure-Vu EVS in Three Poster Presentations at the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting
FORT LAUDERDALE, Fla., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...
Motus GI Granted a U.S. Patent for Prepless Colonoscopy Methods Embodied by the Pure-Vu® System
FORT LAUDERDALE, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...
Motus GI Named a Sole Source Supplier with U.S. Department of Veteran Affairs
FORT LAUDERDALE, Fla., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve...
Motus GI Reports Second Quarter 2022 Financial Results and Provides Business Update
FORT LAUDERDALE, Fla., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) (“Motus GI” or the “Company”), a medical technology company providing endoscopy solutions that improve ...
Motus GI Announces 1-FOR-20 Reverse Stock Split
FORT LAUDERDALE, Fla., July 25, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...
Motus GI to Release Second Quarter Results and Provide a Business Update on August 11
FORT LAUDERDALE, Fla., July 21, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve ...
Motus GI Announces Positive Topline Data From EU Study of the Pure-Vu System in Hard-to-Prepare Patients Presented at Digestive Disease Week 2022
– The Pure-Vu system improved the adequate cleansing rate more than 200% to 97.7% in patients with a history of poor bowel preparation
Motus GI Reports First Quarter 2022 Financial Results and Provides Business Update
FORT LAUDERDALE, Fla., May 12, 2022 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve c...